On November 20, Dr. Tammy Tan, Chairman of HymonBio Co., Ltd., was invited to the University of Leeds in the UK to give a lecture entitled “Advances in Tumor Screening”, which brought in-depth sharing and exchanges of cutting-edge tumor screening technologies to the university’s teachers, students and experts in related fields.
Dr. Tan has been deeply involved in the field of tumor research for many years and has achieved rich scientific research and innovation results. This lecture focused on the latest progress in tumor screening technology. She explained in an easy-to-understand manner the innovative breakthroughs achieved by HymonBio in this field and the development trends of the industry.
During her lecture, Dr. Tan introduced how HymonBio broke through traditional constraints and innovatively integrated intelligent AI with biotechnology. Not only can they detect tumor traces at an earlier stage, but it can also conduct in-depth analysis of methylation mutations of more than 400 genes on the qPCR platform, and rely on the company’s original BIO-AI algorithm to achieve accurate automatic interpretation. With only one tube of blood, 28 common cancers can be detected, and cancer can be detected 3-5 years earlier on average, making large-scale population screening of tumors possible.
Teachers and students from the University of Leeds showed great interest and had an in-depth discussion on technical details, clinical application prospects and challenges faced during the Q&A session.
This lecture promoted academic exchanges and cooperation between China and the UK in the field of tumor screening technology, and further enhanced the visibility and influence of HymonBio on the international research stage.
Post time: Nov-21-2024